Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Ramucirumab and Atezolizumab After Progression on Any Immune Checkpoint Blocker in NSCLC (RamAtezo-1)

NCT03689855 is registered in ClinicalTrials.gov with Washington University School of Medicine as lead sponsor.

NCT NCT03689855
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03689855 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Ramucirumab and Atezolizumab After Progression on Any Immune Checkpoint Blocker in NSCLC (RamAtezo-1)
Lead sponsor
Washington University School of Medicine
Phase
Phase 2
Overall status
Completed
Start date
June 5, 2019
Completion date
April 22, 2024
Enrollment
21 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

non small cell lung cancer, non-small cell lung cancer, nsclc